Human Factors in Digital Health

Slides:



Advertisements
Similar presentations
Elizabeth Mansfield, PhD OIVD Public meeting July 19, 2010
Advertisements

Building a Cradle-to-Grave Approach with Your Design Documentation and Data Denise D. Dion, EduQuest, Inc. and Gina To, Breathe Technologies, Inc.
Module N° 7 – Introduction to SMS
FDA Human Factors of Medical Devices
Testing Medical Devices A Brief Overview © 2005 Max Cortner. Copying and distribution of this document is permitted in any medium, provided this notice.
Strengthening the Medical Device Clinical Trial Enterprise
1 Human Factors/Usability for Medical Devices: An Historical Perspective Ron Kaye Human Factors Premarket Review, Team Leader Office of Device Evaluation,
1 MANUFACTURING AND PRODUCTION OF BIOLOGICAL PRODUCTS (ERT 455) HAZARD ANALYSIS AND CRITICAL CONTROL POINT (HACCP) SYSTEM Munira Mohamed Nazari School.
Medical Device Innovation: Improving Patient Safety One Device at a Time Mary Beth Privitera, M. Design September 22, 2006.
Pre-Market and the QSR Presented by: Dawn Fernandes.
CDRH Software Regulation
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
Center for Devices and Radiological Health U. S. Department of Health and Human Services Al Taylor Acting Chief, Medical Electronics Branch Office of Science.
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
MethodGXP The Solution for the Confusion.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Top 10 Medical Device Citations
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
Product Development Chapter 6. Definitions needed: Verification: The process of evaluating compliance to regulations, standards, or specifications.
March 28, 2006 Combination Products: Preparing for the Journey March 28, 2006 Pamela J. Weagraff Principal Consultant.
Kimberly A. Trautman FDA’s Medical Device Quality System Expert
FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.
Human Factors (HF) - Assessment Method Agenda What is Human Factors? Why do we need HF-Assessment Method ? What is the HF-Assessment Method ? Why.
Ergonomics and Human Factors LECTURE 1. HISTORY OF ERGONOMICS  In the early 1900’s, the production of industry was still largely dependent on human power/motion,
Comp 15 - Usability and Human Factors Unit 4a - Human Factors and Healthcare This material was developed by Columbia University, funded by the Department.
Disclaimer: The views expressed here do not necessarily represent those of the Federal Aviation Administration. Integration of Human Factors in the NextGen.
1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.
© 2011 Partners Harvard Medical International Strategic Plan for Teaching, Learning and Assessment Program Teaching, Learning, and Assessment Center Strategic.
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
CDRH INITIATIVES FOR AGING IN PLACE NIH Aging in Place Workshop September 10-11, 2014 Presented by Mary Brady, MSN, RN Senior Policy Advisor Center for.
Overview of FDA's Regulatory Framework for PET Drugs
Usability and Human Factors Unit 4a Human Factors and Healthcare.
Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Design Documentation Clint Kehres, Brian Krouse, Jenn Shafner.
REGULATION OF COMBINATION PRODUCTS Mark A. Heller Wilmer Cutler Pickering Hale and Dorr LLP MassMEDIC Combination Product Program, March 28, 2006.
IAEA International Atomic Energy Agency Methodology and Responsibilities for Periodic Safety Review for Research Reactors William Kennedy Research Reactor.
Center for Devices and Radiological Health U. S. Department of Health and Human Services Al Taylor Acting Chief, Medical Electronics Branch Office of Science.
Human Factors Engineering Principles of System Design.
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
IAEA International Atomic Energy Agency Development of the Basis Document for Periodic Safety Review for Research Reactors William Kennedy Research Reactor.
Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,
AMERICAS | ASIA PACIFIC | EMEA Medical Devices: Concept to Commercialization How to avoid delays in getting your product cleared/approved by FDA Robert.
Alex Ezrakhovich Process Approach for an Integrated Management System Change driven.
ISO 9001:2015 Subject: Quality Management System Clause 8 - Operation
WORKSHOP ON ACCREDITATION OF BODIES CERTIFYING MEDICAL DEVICES INT MARKET TOPIC 9 CH 8 ISO MEASUREMENT, ANALYSIS AND IMPROVEMENT INTERNAL AUDITS.
Auditing ISO Nancy Pasquan November Introductions I am….. You are….. And we are here to discuss: Auditing ISO Quality Systems for Medical.
Guidance Development Merton V. Smith, Ph.D., J.D. Director International Programs and Product Standards Center for Veterinary Medicine, FDA.
KEVIN BEDAL LISA CARLIN MATT CARROLL ERIN NICHOLS Product Safety & Failure Analysis.
Strengthening the Medical Device Clinical Trial Enterprise
Analysis of Current Maturity Models and Standards
U.S. FDA Center for Devices and Radiological Health Update
The Information Professional’s Role in Product Safety
Risk Communication in Medicines
FDA’s IDE Decisions and Communications
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
NRC’s Category 3 Source Security and Accountability Initiatives
Statistical Approaches to Support Device Innovation- FDA View
The FDA Early Feasibility Study Pilot and the Innovation Pathway
CDRH 2010 Strategic Priorities
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Quality Management Systems – Requirements
Regulatory Oversight of HOF in Finland
Fundamentals of Human Computer Interaction (HCI)
Visualization Using Open-Source Tools: some FDA perspectives
Medical Device Design and Development
Larry Kessler, Sc.D. Director
Timothy B. Cleary, Esq. Meredith Manning, Esq.
Presentation transcript:

Human Factors in Digital Health Kimberly Kontson, Biomedical Engineer, CDRH, FDA Yarmela Pavlovic, Partner, Hogan Lovells US LLP Kimberly Snyder, Senior Partner, Validant Moderated by Karen Corallo, Of Counsel, Skadden, Arps, Slate, Meagher & Flom LLP

Human Factors in Digital Health Medical Devices: FDA Regulation in the Era of Technology and Innovation San Francisco, CA June 6, 2019 Kimberly Kontson, Ph.D. Biomedical Engineer Human-Device Interaction Laboratory Division of Biomedical Physics Office of Science and Engineering Laboratories Center for Devices and Radiological Health

Increasing Complexity Humans are exceptionally good at dealing with complexity, HOWEVER, sometimes the rational action in the moment can have unintended consequences

What is Human Factors (HF)? Ergonomics (or human factors) is the scientific discipline concerned with the understanding of interactions among humans and other elements of a system, and the profession that applies theory, principles, data and methods to design in order to optimize human well-being and overall system performance. International Ergonomics Association (IEA)

Goals of incorporating HF Provide the best possible user experience Combat the medical error problem1 Reduce risk of use errors resulting in harm or compromised medical care Optimized design Original design Low High Risk Level 1www.ncbi.nlm.nih.gov/books/NBK225187

Goals of incorporating HF Provide the best possible user experience Combat the medical error problem1 Reduce risk of use errors resulting in harm or compromised medical care Optimized design Original design Optimized design Original design Low High Risk Level 1www.ncbi.nlm.nih.gov/books/NBK225187

Regulatory Basis for Human Factors in Medical Devices 21 CFR 820.30 Design controls Design input Address intended use of the device, including needs of user/patient Design verification Confirm design output meets design input requirements Design validation Ensure device conforms to user needs…and includes testing of production units under actual or simulated use testing Product development

Regulatory Basis for Human Factors in Medical Devices Medical Devices; Current Good Manufacturing Practice (cGMP); Quality System Regulation Preamble to Final Rule 21 CFR Parts 808, 812, and 820 (61 FR 52502) i.72. “…when designing a device, the manufacturer should conduct appropriate human factors studies, analyses, and tests from the early stages of the design process until that point in development at which the interfaces with the medical professional and the patient are fixed…” i.159. “…FDA emphasizes that any death, even if the manufacturer attributes it to user error, will be considered relevant by FDA and will have a high risk potentially associated with it. User error is still considered to be a nonconformity because human factors and other similar tools should have been considered during the design phase of the device.”

2016 FDA CDRH HF Device Guidance Aims to clarify expectations around: applying HFE to medical device development, when to submit a HF report for a pre-market submission, and the content of the HF report

Information Perception User Cognitive Processing Information Perception Control Action Use error Hazard USER INTERFACE Device Output Input Processing & Reaction Critical task: A user task which, if performed incorrectly or not performed at all, would or could cause serious harm to the patient or user, where harm is defined to include compromised medical care. Adapted from Redmill and Rajan, 1997

HF considerations in Digital Health Mobile Medical Applications Three levels: Regulatory oversight, enforcement discretion, and apps that are not medical devices. HF will be required depending on the evaluated risk level.

HF considerations in Digital Health Define intended users, use environments & UI Identify use-related hazards; identify and categorize critical tasks Develop and implement risk mitigation/control measures Naïve users or negative transfer effects Overreliance on technology output Training expectations Representative use scenarios to evaluate critical tasks Validate use safety and effectiveness Document HFE/UE process

HF considerations in Digital Health Relevant Guidance Documents: https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM263366.pdf https://www.fda.gov/MedicalDevices/DigitalHealth/ucm562577.htm

Requests for Feedback and Meetings for Medical Device Submissions Q-submission Program https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program Pre-Submission - Informational Meeting Study Risk Determination Agreement Meeting Determination Meeting Submission Issue Meeting Day 100 Meeting

CDRH Human Factors Mailbox HFPMET@fda.hhs.gov

Human Factors in Digital Health Kimberly Kontson, Biomedical Engineer, CDRH, FDA Yarmela Pavlovic, Partner, Hogan Lovells US LLP Kimberly Snyder, Senior Partner, Validant Moderated by Karen Corallo, Of Counsel, Skadden, Arps, Slate, Meagher & Flom LLP